A Bayesian Reanalysis of a Trial of Psilocybin Versus Escitalopram for Depression-Reference-Cited by-同舟云学术

A Bayesian Reanalysis of a Trial of Psilocybin Versus Escitalopram for Depression

Published:2023-03-01 Issue:1 Volume:1 Page:18-26
ISSN:2831-4425
Container-title:Psychedelic Medicine
language:en
Short-container-title:Psychedelic Medicine

Author:

Nayak Sandeep M.¹^ORCID,Bari Bilal A.²,Yaden David B.¹,Spriggs Meg J.³,Rosas Fernando E.³,Peill Joseph M.³,Giribaldi Bruna³,Erritzoe David³,Nutt David J.³,Carhart-Harris Robin⁴

Affiliation:

1. Behavioral Pharmacology Research Unit, Center for Psychedelic and Consciousness Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

2. Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA.

3. Department of Medicine, Centre for Psychedelic Research, Imperial College, London, United Kingdom.

4. Psychedelics Division, Neuroscape, Department of Neurology, University of California, San Francisco, California, USA.

Publisher

Mary Ann Liebert Inc

Link

https://www.liebertpub.com/doi/pdf/10.1089/psymed.2022.0002

Reference33 articles.

1. Trial of Psilocybin versus Escitalopram for Depression

2. Frequentist versus Bayesian approaches to multiple testing

3. The Interplay of Bayesian and Frequentist Analysis

4. Using Bayes factor hypothesis testing in neuroscience to establish evidence of absence

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Psilocybin induces acute anxiety and changes in amygdalar phosphopeptides independently from the 5-HT2A receptor;iScience;2024-05

2. Psychedelikagestützte Psychotherapie in der Behandlung depressiver Störungen;Nervenheilkunde;2023-06